Key points are not available for this paper at this time.
e19013 Background: Bispecific antibodies (BsAbs) are emerging as a promising new immunotherapy modality in patients with lymphoma. Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells, was first to receive approval for relapsed or refractory follicular lymphoma. Here, we report the safety and efficacy of Mosunetuzumab as a first line therapy in combination or monotherapy regimen in non-hodgkin lymphoma. Methods: A literature search was performed on PubMed with keywords for “Mosunetuzumab” AND “lymphoma”. The search was performed from the inception of data till 1/1/2024. A total of 237 articles were screened and three non-randomized clinical trials (nRCTs, N=124) were included. PRISMA guidelines were followed while conducting this systematic review. Results: In 3 clinical trials, 54 patients were treated with mosunetuzumab monotherapy, 40 with mosunetuzumab + cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), and 30 with subcutaneous mosunetuzumab. 94 patients had diffuse large B-cell lymphoma (DLBCL), and 30 patients had follicular lymphoma. ORR, CR, and PR were reported in 56%, 43%, and 13% patients, respectively, treated with mosunetuzumab monotherapy in DLBCL. ORR, CR, and PR were reported in 87.5%, 85%, and 2.5% patients, respectively, treated with mosunetuzumab + CHOP in DLBCL. ORR, CR, and PR were reported in 96%, 83%, and 12.5% patients, respectively, treated with subcutaneous mosunetuzumab in follicular lymphoma. Neutropenia, thrombocytopenia, infections, and fatigue were common adverse effects given in the table. Conclusions: Mosunetuzumab with CHOP showed higher efficacy results and was well tolerated by most of the patients and can be an option to achieve high response rates in DLBCL. Subcutaneous mosunetuzumab was active in follicular lymphoma with manageable toxicity in follicular lymphoma. However, long-term results are needed to determine the durability of responses and long-term safety and survival rates with these regimens. Table: see text
Jumean et al. (Sat,) studied this question.